论文部分内容阅读
LAK细胞联合rIL-2目前被认为是抗肿瘤、抗转移免疫治疗中最为有效的方法之一。其疗效除了与输入的LAK细胞数量有关外,还与IL-2的质和量相关,随着国产rIL-2的面世,此疗法日益广泛。本文较为系统地研究了国产rIL-2在肿瘤过继免疫治疗上的可行性、安全性及有效性,为临床应用提供了依据。在此基础上,我们应用国产rIL-2联合同种及自体LAK细胞对297例恶性肿瘤患者进行了临床实验研究,包括癌性胸水157例,腹水41例,宫颈癌20例,黑色素瘤23例,肾癌7例,淋巴肉瘤14例,肝癌14例,肺癌21例。
LAK cells combined with rIL-2 is currently considered as one of the most effective methods for anti-tumor and anti-metastasis immunotherapy. Its efficacy is related to the amount of LAK cells imported, but also related to the quality and quantity of IL-2. With the advent of domestic rIL-2, this therapy has become increasingly widespread. This article systematically studied the feasibility, safety and effectiveness of domestic rIL-2 in adoptive immunotherapy of tumors, and provided basis for clinical application. On this basis, we used domestic rIL-2 combined with allogeneic and autologous LAK cells to perform clinical trials on 297 patients with malignant tumors, including 157 cases of malignant pleural effusion, 41 cases of ascites, 20 cases of cervical cancer, and 23 cases of melanoma. There were 7 cases of kidney cancer, 14 cases of lymphosarcoma, 14 cases of liver cancer, and 21 cases of lung cancer.